Pioneering New Technologies for Developing Groundbreaking ER Stress Therapeutics
The ER Stress Research Institute was established in January 2017 as a startup originating from Tokushima University. ER stress has been known to contribute to the onset and progression of various diseases. Our goal is to develop therapeutics for diseases related to ER stress and ultimately help overcome them. To achieve this, we have established an ER stress drug discovery platform, collaborating with pharmaceutical companies both domestically and internationally.
The ER stress drug discovery platform comprises three core technologies,
including the ER Stress Pathology Connector, ER Stress Screener, and ER Stress Evaluator.
A comprehensive database integrating our proprietary data with publicly available clinical data, connecting disease pathology to its root cause, ER stress. This database identifies key therapeutic targets, serving as a valuable resource for drug discovery.
A collection of assay techniques offering comprehensive, high-throughput screening capabilities. This technology identifies drug candidates that modulate ER stress from a vast compound library, facilitating drug discovery.
A suite of systematic evaluation models, including model mice, that can assess all ER stress responses. These models assist in the evaluation of therapeutic candidates aimed at modulating ER stress
Therapeutic and Mode of Action:
Chemical chaperones that inhibit the aggregation of misfolded proteins.
Applications:
Neurodegenerative diseases, among others.
Therapeutic and Mode of Action:
UPR activators that activate the unfolded protein response (UPR).
Applications:
Autoimmune diseases, among others.
Therapeutic and Mode of Action:
UPR inhibitors that inhibit the unfolded protein response (UPR).
Applications:
Cancer, among others.
| Company Name | ER Stress Research Institute, Inc. |
|---|---|
| Location | 3-18-15 Kuramoto, Tokushima, Japan 770-8530 |
| President and CEO | Seiichi Oyadomari, M.D., Ph.D. |
| Founded | January 2017 |
| Contact | +81-88-633-9456 |